AstraZeneca Pharma India Limited
Regd. Office :'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Financial results for the quarter and six months ended 30 September 2012

Part I — **Rs in lakhs (except for number of shares)**

Sl No.	Particulars	3 months ended 30/09/2012 (Unaudited)	3 months ended 30/06/2012 (Unaudited)	3 months ended 30/09/2011 (Unaudited)	6 months ended 30/09/2012 (Unaudited)	6 months ended 30/09/2011 (Unaudited)	Previous year ended 31/03/2012 (Audited)
1	**Income from operations**						
	a) Net sales/ income from operations (net of excise duty)	**9,922.82**	9,126.08	14,862.43	**19,048.90**	28,610.66	53,127.97
	b) Other operating income	**4.88**	2.79	4.43	**7.67**	10.47	24.05
	Total income from operations (net)	**9,927.70**	9,128.87	14,866.86	**19,056.57**	28,621.13	53,152.02
2	**Expenses**						
	(a) Cost of materials consumed	**1,379.29**	715.85	1,993.81	**2,095.14**	4,392.90	7,151.68
	(b) Purchase of stock-in-trade	**2,429.15**	2,623.54	2,620.13	**5,052.69**	5,768.57	11,923.13
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	**563.69**	452.24	(93.05)	**1,015.93**	(1,484.67)	(1,210.38)
	(d) Employee benefits expense	**3,859.01**	3,339.55	3,523.44	**7,198.56**	6,877.06	16,191.24
	(e) Depreciation and amortisation expense	**250.31**	175.14	191.28	**425.45**	364.02	733.86
	(f) Other expenses	**3,701.78**	3,924.42	3,639.80	**7,626.20**	7,367.26	16,070.05
	Total expenses	**12,183.23**	11,230.74	11,875.41	**23,413.97**	23,285.14	50,859.58
3	**Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)**	**(2,255.53)**	(2,101.87)	2,991.45	**(4,357.40)**	5,335.99	2,292.44
4	Other income	**173.92**	783.53	140.96	**957.45**	285.19	633.04
5	**Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)**	**(2,081.61)**	(1,318.34)	3,132.41	**(3,399.95)**	5,621.18	2,925.48
6	Finance costs	**-**	-	-	**-**	-	-
7	**Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)**	**(2,081.61)**	(1,318.34)	3,132.41	**(3,399.95)**	5,621.18	2,925.48
8	Exceptional items	**-**	-	-	**-**	-	-
9	**Profit/ (loss) from ordinary activities before tax (7+8)**	**(2,081.61)**	(1,318.34)	3,132.41	**(3,399.95)**	5,621.18	2,925.48
10	Tax expense (Refer note 6)	**2,429.97**	(503.74)	1,024.01	**1,926.23**	1,837.96	948.97
11	**Net profit/(loss) from ordinary activities after tax (9-10)**	**(4,511.58)**	(814.60)	2,108.40	**(5,326.18)**	3,783.22	1,976.51
12	Extraordinary Item	**-**	-	-	**-**	-	-
13	**Net profit/(loss) for the period (11-12)**	**(4,511.58)**	(814.60)	2,108.40	**(5,326.18)**	3,783.22	1,976.51
14	Paid-up equity share capital	**500.00**	500.00	500.00	**500.00**	500.00	500.00
	(Face value of Rs 2 per equity share)						
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year						18,428.52
16	**Basic and diluted earnings (Rs) per share (not annualised)**	**(18.05)**	(3.26)	8.43	(21.30)	15.13	7.91
Part II							
A	**Particulars of shareholding**						
1	**Public shareholding**						
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
2	**Promoters and promoter group shareholding**						
	a) Pledged/Encumbered						
	- Number of shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%

B.	Particulars	3 months ended 30/09/2012
	Investor complaints	
	Pending at the beginning of the quarter	**Nil**
	Received during the quarter	**10**
	Disposed of during the quarter	**10**
	Remaining unresolved at the end of the quarter	**Nil**

Notes:

1. The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 7 November 2012.
2. The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
3. Other income for the quarter ended 30 June 2012 and the period ended 30 September 2012 includes an amount of Rs 693.49 lakhs towards compensation for factory land acquired by National Highway Authority of India in the previous year.
4. At the end of the previous financial year, the factory experienced interruptions to the supply of certain products. While several products have been returned to the market, the Company continues to pursue a remediation plan to address these interruptions. As a result of these interruptions, revenues and the financial results for the current quarter and the half year ended 30 September 2012 are lower compared to the prior period.
5. In view of the inadequacy of profit during the current half year, the remuneration paid to the Managing Director up to 31 August 2012 (date of his resignation) and that paid/ payable to the Whole Time Director is subject to compliance with the requirements of Schedule XIII to the Companies Act, 1956
6. Tax expense represents deferred tax assets amounting to Rs 2,429.97 lacs which have been charged to the profit and loss for the quarter ended 30 September 2012.
7. The above statement of financial results have been reviewed by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filed with the stock exchange and is also available on the Company's website.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Bangalore
Dated: 7 November 2012

Ruby Lau
Whole Time Director

AstraZeneca Pharma India Limited
Regd. Office :'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Segment wise revenue, results and capital employed

(Rs in lakhs)

Sl.no.	Particulars	3 months ended 30/09/2012 (Unaudited)	3 months ended 30/06/2012 (Unaudited)	3 months ended 30/09/2011 (Unaudited)	6 months ended 30/09/2012 (Unaudited)	6 months ended 30/09/2011 (Unaudited)	Previous year ended 31/03/2012 (Audited)
1	**Segment revenue**						
	(a) Healthcare	**9,259.78**	8,327.42	14,205.80	**17,587.20**	27,153.66	49,977.92
	(b) Others	**667.92**	801.45	661.06	**1,469.37**	1,467.47	3,174.10
	Total	**9,927.70**	9,128.87	14,866.86	**19,056.57**	28,621.13	53,152.02
	Less: Inter-segment revenue	**-**	-	**-**	**-**	-	-
	Net income from operations	**9,927.70**	9,128.87	14,866.86	**19,056.57**	28,621.13	53,152.02
2	**Segment results**						
	Profit/(loss) before tax and interest						
	(a) Healthcare	**(2,306.31)**	(2,078.25)	2,923.52	**(4,384.56)**	5,240.58	2,165.28
	(b) Others	**50.78**	(23.62)	67.93	**27.16**	95.41	127.16
	Total	**(2,255.53)**	(2,101.87)	2,991.45	**(4,357.40)**	5,335.99	2,292.44
	Add: Other income	**173.92**	783.53	140.96	**957.45**	285.19	633.04
	Less: Interest	**-**	-	**-**	**-**	-	
	Total profit/(loss) before tax	**(2,081.61)**	(1,318.34)	3,132.41	**(3,399.95)**	**5,621.18**	2,925.48
3	**Capital employed**						
	(a) Healthcare	**9,279.12**	13,056.25	14,973.36	**9,279.12**	14,973.36	11,722.25
	(b) Others	**454.42**	619.21	463.97	**454.42**	463.97	817.67
	(c) Unallocated	**3,868.80**	4,438.47	6,314.85	**3,868.80**	6,314.85	6,388.60
	Total	**13,602.34**	18,113.93	21,752.18	**13,602.34**	21,752.18	18,928.52

Notes :

1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

AstraZeneca Pharma India Limited
Regd Office : "Avishkar' Off Bellary Road , Hebbal Bangalore - 560 024
Statement of assets and liabilities

(Rs in lakhs)

Sl.no.		Particulars	As at 30 September 2012 (Unaudited)	As at 31 March 2012 (Audited)
A		**EQUITY AND LIABILITIES**		
	1	**Shareholders' funds**		
		(a) Share capital	500.00	500.00
		(b) Reserves and Surplus	13,102.34	18,428.52
		(c) Money received against share warrants	-	-
		Sub-total - Shareholders' funds	13,602.34	18,928.52
	2	**Share application money pending allotment**	-	-
	3	**Non-current liabilities**		
		(a) Long-term borrowings	-	-
		(b) Deferred tax liabilities (net)	-	-
		(c) Other long-term liabilities	48.44	54.44
		(d) Long-term provisions	-	-
		Sub-total - Non-current liabilities	48.44	54.44
	4	**Current liabilities**		
		(a) Short-term borrowings	-	-
		(b) Trade payables	5,988.32	1,776.54
		(c) Other current liabilities	8,187.62	8,619.33
		(d) Short-term provisions	2,274.84	4,829.60
		Sub-total - Current liabilities	16,450.78	15,225.47
		TOTAL - EQUITY AND LIABILITIES	**30,101.56**	**34,208.43**
B		**ASSETS**		
	1	**Non-current assets**		
		(a) Fixed assets	9,498.54	9,018.24
		(b) Non-current investments	0.57	0.57
		(c) Deferred tax assets (net)	-	1,776.23
		(d) Long-term loans and advances	2,969.14	3,460.40
		(e) Other non-current assets	196.92	196.92
		Sub-total - Non-current assets	12,665.17	14,452.36
	2	**Current assets**		
		(a) Current investments	-	-
		(b) Inventories	6,576.27	7,509.69
		(c) Trade receivables	4,171.50	3,230.79
		(d) Cash and bank balances	2,946.71	5,365.07
		(e) Short-term loans and advances	2,069.68	2,415.95
		(f) Other current assets	1,672.23	1,234.57
		Sub-total - Current assets	17,436.39	19,756.07
		TOTAL - ASSETS	**30,101.56**	**34,208.43**